Drug Trial Radar · NCT07546812
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 7, 2026
Primary completion
Jan 2030
Study completion Jan 2030
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Apr 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based combinations in in participants with human epidermal growth factor receptor 2 (HER2)-Negative, unresectable, recurrent, and/or metastatic, gastroesophageal junction (GEJ), and esophageal adenocarcinomas. The primary objective of this study is to assess the effect of DEN as a monotherapy or in combination with nivolumab (NIVO) or ramucirumab (RAM) and paclitaxel (PAC) on objective response rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST Version1.1).
Conditions
- HER2-negative
- Gastroesophageal Junction
- Esophageal Adenocarcinoma
- Gastric Adenocarcinoma
Interventions
DenikitugDrug
Administered Intravenously
NivolumabDrug
Administered Intravenously
RamucirumabDrug
Administered Intravenously
PaclitaxelDrug
Administered Intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to 4 years
Locations
16 sites in 5 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts
New York Oncology Hematology
Albany, New York
Weill Cornell Medicine - New York Presbyterian Hospital
New York, New York
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Hollywood Private Hospital
Nedlands, Western Australia, Australia
Centre Leon Berard, department of medical oncology
Lyon, France
Institut Paoli-Calmettes, department of medical oncology
Marseille, France
Seoul National University Hospital
Seoul, South Korea
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario de Navarra
Pamplona, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.